Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 27;11:5420. doi: 10.1038/s41467-020-19176-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Plasma was collected from RA patients prior to the initiation of treatment with DMARD and lipid mediator concentrations established using LC-MS/MS-based lipid mediator profiling. a, b PLS-DA analysis of peripheral blood lipid mediator concentrations for lympho-myeloid (lymphoid), diffuse-myeloid (myeloid) and pauci-immune-fibroid (fibroid) pathotypes. a 3-dimensional score plot. b Variable importance in projection (VIP) scores of 15 lipid mediators with the greatest differences in concentrations between the three groups. Results are representative of n = 18 for Fibroid n = 17 for myeloid and n = 19 for lymphoid. c Pathway analysis for the differentially expressed mediators from the DHA and n-3 DPA bioactive metabolomes in DMARD non-responders (Non-Resp) when compared to DMARD responders (Resp) for each pathotype. Statistical differences between the normalised concentrations (expressed as the fold change) of the lipid mediators from the Non-Resp and Resp groups were determined using two-sided t test followed by a multiple comparison correction using Benjamini–Hochberg procedure. Up- or downregulated mediators are denoted with using upward and downward facing triangles, respectively, and on changes of the node’s size. Bolded mediators represent statistical differences between the two groups when adjusted p value <0.05. Results are representative of n = 18 for fibroid Resp, n = 15 for fibroid Non-Resp, n = 19 for lymphoid Resp, n = 10 for lymphoid Non-Resp, n = 22 for myeloid Resp, n = 15 for myeloid Non-Resp. d Classification accuracies for each class (sensitivity and specificity) of the RvD4, 10S,17S-diHDPA, 15R-LXA₄ and MaR1_{n-3 DPA} model created using the specific dataset for the different pathotypes (fibroid, lymphoid and myeloid). Green indicates the samples that were predicted as Resp while blue indicates predicted Non-Resp. Percentages indicate true positives (Resp class) and true negatives (Non-Resp class). All the models were created using the random forest methodology (“randomForest” package from R). Source data are provided as a Source data file.